CLNN | tickerfilter.com

Fundamental analysis

32%

Profitability 0%

Dept financing 50%

Liquidity 75%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.87%

1 Month

-1.30%

3 Months

-8.47%

6 Months

-28.39%

1 Year

922.52%

2 Year

233.82%

Key data

Stock price

$4.54

P/E Ratio

0.00

DAY RANGE

$4.44 - $4.59

EPS

-$2.47

52 WEEK RANGE

$0.26 - $6.96

52 WEEK CHANGE

$932.76

MARKET CAP

29.698 M

YIELD

N/A

SHARES OUTSTANDING

6.470 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.30

PUBLIC FLOAT

AVERAGE 10 VOLUME

$31,689

AVERAGE 30 VOLUME

$41,768

Company detail

CEO: Robert D. Etherington
Region: US
Website: clene.com
Employees: 100
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Clene Inc. focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis. The company also markets and distributes dietary supplements.

CLNN - Clene Inc.